ASH highlights five recommendations from other organizations.
Vistogard (uridine triacetate)
Now FDA-approved for treatment of overdoses of fluorouracil or capecitabine.
AARP study finds that caregivers provide much more than basic care.
Earlier Cervical Cancer Diagnosis
Linked to expansion of health insurance coverage.
Diagnosis and management guidelines.
Updated Antiemetic Guidelines
ASCO issues advice on NEPA for CINV.
ASCO issues updated statement on its use and healthcare provider education.
Contralateral Prophylactic Mastectomies
Rates are on the rise for both men and women.
Symptoms of Metastasis
Not always reported by men with prostate cancer.
Why do some smokers live long beyond their life expectancy?
Study finds some individuals have genetic variants that allow them to have long-term exposure to a carcinogen without developing lung cancer.
Improvement or a necessary evil?
Aspirin to Prevent Colon Cancer
USPSTF issues draft recommendations.
A practical solution may be topical lidocaine application.
Incidence is rising, mainly because of successful treatment of first cancer.
Study suggests that "vaping" is likely to lead to tobacco smoking among adolescents.
Communicating Biopsy Results
Clinicians suggest that telemedicine may be helpful.
Patients' Mental Health
Meta-analysis of 148 studies confirms benefit of spirituality and religion.
Encouraging News About Ovarian Cancer Survival
Study finds long-term survival is not unusual.
Physicians appear to be the drivers of hospice care.
The Oncology Drug Shortage: At Practice Level, Shortages Become Personal and Painful
Providing oncology care is in itself intense and challenging, and the ongoing shortage of oncology drugs has made clinical practice even more challenging as we deal with the shortage on a very personal level.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
2 Clarke Drive Cranbury, NJ 08512